Intervention
Fulvestrant
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 299 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownRash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15
RECRUITINGA Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.NCT07666555 · 2026-06-06
RECRUITINGStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerNCT07604571 · 2026-05-28
RECRUITINGSapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerNCT07558733 · 2026-04-22
RECRUITINGA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerNCT07405801 · 2026-04-07
RECRUITINGTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerNCT07368998 · 2026-02-18
RECRUITINGStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsNCT07287917 · 2026-01-26
RECRUITINGA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerNCT07347600 · 2026-01-21
RECRUITINGStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359 · 2025-12-29
RECRUITINGA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23
RECRUITINGA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22
RECRUITINGA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyNCT07330544 · 2025-11-24
RECRUITINGIparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerNCT07180160 · 2025-09-25
RECRUITINGAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyNCT07117630 · 2025-09-25
RECRUITINGPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26
RECRUITINGORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsNCT06998407 · 2025-08-20
RECRUITINGA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05
RECRUITINGA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01
RECRUITINGA Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNCT07029399 · 2025-03-25
RECRUITINGA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNCT06856200 · 2025-02-28
RECRUITINGBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932 · 2025-02-04
RECRUITINGPhase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsNCT06784193 · 2024-12-16
RECRUITINGOpen-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29
RECRUITINGGenetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorNCT05933395 · 2024-09-23
RECRUITINGSequential Therapies Modeled on Evolutionary Dynamics for Breast CancerNCT06409390 · 2024-08-14
RECRUITINGSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01
RECRUITINGFunctional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22
RECRUITINGSafety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerNCT06515470 · 2024-07-03
RECRUITINGBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01
RECRUITINGStudy of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30
RECRUITINGLiquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerNCT05601440 · 2023-06-13
RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07
RECRUITINGFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerNCT05735080 · 2023-03-28
RECRUITINGVS-6766+Abema+Fulv in Met HR+/HER- BCNCT05608252 · 2023-02-23
RECRUITINGA Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerNCT05683418 · 2023-02-15
RECRUITINGImmunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCNCT05720260 · 2023-01-17
RECRUITINGPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11
RECRUITINGEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 InhibitorNCT05536128 · 2022-12-31
RECRUITINGA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerNCT06954961 · 2022-09-15
RECRUITINGRibociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerNCT05467891 · 2022-09-13
RECRUITINGAnastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerNCT05524584 · 2022-08-31
RECRUITINGA Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705 · 2022-05-11
RECRUITINGLenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorNCT05181033 · 2021-12-27
RECRUITINGFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerNCT05216432 · 2021-12-08
RECRUITINGStudy of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · 2020-11-16
RECRUITINGFulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerNCT04263298 · 2018-05-01
RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30
RECRUITINGEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreNCT02476786 · 2017-01-17
RECRUITINGRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.NCT07679269 · 2026-12-15
NOT_YET_RECRUITINGA Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNCT07748208 · 2026-10-30
NOT_YET_RECRUITINGA Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.NCT07619066 · 2026-10-04
NOT_YET_RECRUITINGFulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNCT07716046 · 2026-10-01
NOT_YET_RECRUITINGA Phase 1/2a Study of K-1728 in Advanced Solid TumorsNCT07861932 · 2026-10-01
NOT_YET_RECRUITINGA Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNCT07811232 · 2026-09-01
NOT_YET_RECRUITINGTrastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast CancerNCT07857226 · 2026-09-01
NOT_YET_RECRUITINGStudy of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07570966 · 2026-06-30
WITHDRAWNStudy of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerNCT07408089 · 2026-02-25
TERMINATEDA Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerNCT07235618 · 2026-01-05
NOT_YET_RECRUITINGCommon conditions
Breast Cancer108Metastatic Breast Cancer60Advanced Breast Cancer34Breast Neoplasms24HER2-negative Breast Cancer13Anatomic Stage IV Breast Cancer AJCC v812Advanced Solid Tumor8Anatomic Stage III Breast Cancer AJCC v87HER2/Neu Negative7Metastatic Breast Carcinoma7Estrogen Receptor Positive6Hormone Receptor Positive Tumor6Prognostic Stage IV Breast Cancer AJCC v86Recurrent Breast Carcinoma6Stage IV Breast Cancer AJCC v6 and v76Breast Cancer Metastatic5Breast Neoplasm5Hormone Receptor Positive Breast Carcinoma5Hormone Receptor-positive Breast Cancer5Locally Advanced Breast Cancer5Ovarian Cancer5Advanced Solid Tumors4Breast Carcinoma4Estrogen Receptor Positive Breast Cancer4Hormone Receptor Positive HER-2 Negative Breast Cancer4
Leading sponsors
AstraZeneca27Novartis Pharmaceuticals22Eli Lilly and Company13Hoffmann-La Roche12Fudan University11Pfizer10National Cancer Institute (NCI)8Dana-Farber Cancer Institute6Genentech, Inc.5Memorial Sloan Kettering Cancer Center5Spanish Breast Cancer Research Group5MedSIR4Washington University School of Medicine4BeOne Medicines3Consorzio Oncotech3
Trial status mix
COMPLETED107
ACTIVE_NOT_RECRUITING54
RECRUITING50
TERMINATED43
UNKNOWN28
WITHDRAWN9
NOT_YET_RECRUITING8
Phase mix
PHASE2167
PHASE190
PHASE353
PHASE46
EARLY_PHASE12
NA2
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.